Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2025-06-06 Legal Proceedings Report
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Updates
Legal Proceedings Report Classification · 100% confidence The document is an order sheet from the National Company Law Tribunal (NCLT) related to a legal proceeding involving Orchid Pharma Ltd. It contains details of hearings, counsel appearances, case numbers, and orders disposing of an application. There is no financial data, earnings information, or corporate governance details. The content is clearly related to legal proceedings and court orders rather than financial reports or corporate announcements. Therefore, the document fits best under Legal Proceedings Report (LTR). The document length is short and it is not an announcement of a report but a legal order itself.
2025-06-06 English
Giving guarantees/indemnity/ becoming a surety for third party
Regulatory Filings Classification · 95% confidence The document is a formal disclosure filed by Orchid Pharma Limited to stock exchanges (NSE and BSE) regarding a corporate guarantee given on behalf of its wholly owned subsidiary, Orchid Bio-Pharma Limited. It references specific SEBI regulations and circulars related to disclosure requirements under the Listing Obligations and Disclosure Requirements Regulations, 2015. The content is focused on providing details about the corporate guarantee, including the nature, amount, and regulatory compliance. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory announcement disclosing a material event related to corporate guarantees, which fits under general regulatory announcements and compliance disclosures. It is not an annual report, earnings release, or any other detailed financial report. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 4403 characters, which is relatively short and consistent with a regulatory announcement rather than a full report.
2025-06-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call held by Orchid Pharma Limited on May 26, 2025, discussing the financial results for the fourth quarter and full fiscal year ending March 31, 2025. It includes management commentary on sales, EBITDA, operational challenges, project updates, and Q&A with analysts. The presence of a full transcript of the call, including management remarks and Q&A, clearly identifies this as a Call Transcript (CT). The document is about 15,000 characters long, contains substantive discussion of financial results and outlook, and is not merely an announcement or summary. Therefore, the appropriate classification is Call Transcript (CT).
2025-06-02 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated May 29, 2025, from Orchid Pharma Limited addressed to stock exchanges (NSE and BSE). It informs about the receipt of the Establishment Inspection Report (EIR) from the USFDA with a 'VAI' status, indicating compliance with regulatory standards. The document is brief (1775 characters) and serves as an intimation or notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed regulatory filings but is a regulatory update to the exchanges. According to the rules, such short announcements that inform about regulatory or compliance matters without detailed financial or operational data fall under Regulatory Filings (RNS).
2025-05-29 English
Updates
Regulatory Filings Classification · 95% confidence The document text is extremely short (416 characters) and contains only a digital signature block with no substantive content related to financial reports, announcements, or filings. There is no mention of any report type, financial data, or corporate actions. Given the lack of content and the nature of the text, it does not fit any specific filing category and should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit elsewhere.
2025-05-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a notification dated May 26, 2025, from Orchid Pharma Limited to stock exchanges regarding the audio recording of an Analysts/Investors Earnings Call discussing the Audited Financial Results for the quarter and financial year ended March 31, 2025. It references SEBI regulations and confirms the call was held via audio conference. The document provides a link to the audio recording but does not contain the transcript or detailed financial data itself. The document length is 2878 characters, which is relatively short and primarily serves as an announcement of the earnings call recording availability. According to the rules, such announcements about earnings calls or their recordings are classified as Call Transcript (CT) if the full transcript is provided, but here only an audio recording link is given, and the document is an announcement rather than the transcript itself. However, since the document is about the earnings call and not the earnings release (which would be a summary of financial results), and it is not the transcript but an announcement of the audio recording, the best fit is Call Transcript (CT) category, as it relates to the earnings call content. Confidence is high because the document explicitly states it is about the earnings call audio recording and references the financial results discussed therein.
2025-05-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.